Tibolone (Livial) - Comprehensive Research Paper

Document Information

• Product Name: Tibolone
• Brand Name(s): Livial (primary), Tibofem, Tibogest, others
• Category: Synthetic Steroid / STEAR (Selective Tissue Estrogenic Activity Regulator)
• Paper Number: 46 of 76
• Last Updated: 2025-12-26

Table of Contents

1. Summary
2. Mechanism of Action
3. FDA-Approved Indications
4. Dosing and Administration
5. Pharmacokinetics
6. Side Effects and Adverse Reactions
7. Drug Interactions
8. Contraindications
9. Special Populations
10. Monitoring Parameters
11. Cost and Availability
12. Clinical Evidence Summary
13. Comparison with Alternatives
14. Goal Archetype Integration
15. Age-Stratified Dosing
16. Drug Interactions (Expanded Clinical Guidance)
17. Bloodwork Impact
18. Protocol Integration
19. Storage and Handling
20. References

Goal Relevance:

• Manage hot flashes and night sweats during menopause
• Support vaginal health and reduce dryness for postmenopausal women
• Improve mood and emotional well-being during menopause
• Enhance bone strength and prevent osteoporosis in postmenopausal women
• Boost libido and sexual function for women experiencing menopausal symptoms
• Reduce the risk of vertebral fractures in older women

1. Summary

Overview

Tibolone is a synthetic steroid compound that possesses a unique combination of estrogenic, progestogenic, and androgenic properties, distinguishing it from all other hormone replacement options. Originally developed by Organon Pharmaceuticals (now part of Merck), tibolone has been used in clinical practice in Europe, Asia, Australia, and many other regions for nearly four decades, primarily for the management of menopausal symptoms and prevention of postmenopausal osteoporosis.

Classification

Tibolone is classified as a Selective Tissue Estrogenic Activity Regulator (STEAR), reflecting its unique mechanism whereby the parent compound and its metabolites exert different hormonal activities in different tissues. This tissue selectivity arises from local metabolism rather than selective receptor binding as seen with SERMs.

Chemical Classification

• Chemical class: 19-Nortestosterone derivative
• Related compounds: Structurally related to norethindrone and other 19-nortestosterone progestins
• Regulatory classification: In Canada, tibolone is classified as a Schedule IV controlled substance under the Controlled Drugs and Substances Act due to its anabolic steroid activity

Regulatory Status Summary

• United States: NOT FDA approved (received "Not Approvable" letter in June 2006)
• European Union: Approved for menopausal symptoms and osteoporosis prevention
• Global approval: Approved in approximately 90 countries for menopausal symptoms; 45 countries for osteoporosis prevention
• Key markets: Europe, Asia, Australia, Latin America

Clinical Positioning

Tibolone occupies a unique niche in menopausal hormone therapy:

Advantages:

• Single-compound therapy (no need for separate estrogen + progestogen)
• Improves vasomotor symptoms, vaginal symptoms, mood, and sexual function
• Prevents bone loss
• Less breast tenderness than conventional HRT
• Less vaginal bleeding than combined estrogen-progestogen
• Positive effects on libido (androgenic activity)

Disadvantages:

• Not available in the United States
• Increased breast cancer recurrence risk (contraindicated after breast cancer)
• Increased stroke risk in women over age 60
• Less effective for vasomotor symptoms than combined HRT
• Complex regulatory status

Important Safety Signals

Two major clinical trials fundamentally shaped tibolone's safety profile:

1. LIFT Trial (Long-Term Intervention on Fractures with Tibolone):

   • Demonstrated significant vertebral fracture reduction (HR 0.50)
   • Trial stopped early due to increased stroke risk (HR 2.30)
   • Stroke risk primarily in women aged 60-85

2. LIBERATE Trial (Livial Intervention Following Breast Cancer):

   • Demonstrated 40% increased risk of breast cancer recurrence (HR 1.40)
   • Contraindicated in women with breast cancer history

2. Mechanism of Action

Multi-Receptor Activity Profile

Overview of Hormonal Activity

Unlike conventional hormone therapies that contain discrete estrogenic and progestogenic components, tibolone is a prodrug that is rapidly metabolized into three primary metabolites, each with distinct hormonal activities:

Tissue-Selective Metabolism

The tissue selectivity of tibolone arises from differential local metabolism:

In Vaginal/Bone/Brain Tissue:

• Active 3α- and 3β-hydroxy metabolites predominate
• Estrogenic effects support vaginal health, bone preservation, mood

In Breast and Endometrial Tissue:

• Local sulfatase inhibition reduces estrogen activation
• Δ4-isomer provides progestogenic opposition
• Net antiproliferative effect in endometrium

In Liver:

• First-pass metabolism generates circulating metabolites
• Effects on lipids and coagulation factors

Estrogen Receptor Activity

Hydroxy-Metabolite Binding

The 3α-hydroxytibolone and 3β-hydroxytibolone metabolites are the primary drivers of estrogenic activity:

Receptor Binding Characteristics:

• ERα affinity: High (approximately 10% that of estradiol)
• ERβ affinity: Lower than ERα
• Full agonist activity at both receptors
• No SERM-like tissue selectivity at receptor level

Tissue Effects:

• Bone: Inhibits osteoclast activity, reduces bone resorption
• Vagina: Improves epithelial maturation, reduces atrophy
• Brain: Affects mood, cognition, thermoregulation
• Cardiovascular: Improves lipid profile (LDL reduction)

Sulfatase Inhibition in Breast Tissue

A key mechanism distinguishing tibolone from conventional estrogen therapy:

Local Inactivation:

• 3α-hydroxytibolone inhibits steroid sulfatase in breast tissue
• Reduces conversion of estrone sulfate to active estrone
• Net effect: Decreased local estrogen exposure
• May explain lower breast cancer incidence in LIFT trial

Progesterone Receptor Activity

Δ4-Tibolone Progestogenic Effects

The Δ4-isomer demonstrates progestogenic activity:

Receptor Characteristics:

• Progesterone receptor agonist
• Moderate affinity (approximately 15% that of progesterone)
• Functional progestogenic effects in endometrium

Clinical Significance:

• Protects endometrium from estrogen-induced hyperplasia
• Eliminates need for separate progestogen
• Explains lower endometrial cancer risk compared to unopposed estrogen

Androgen Receptor Activity

Androgenic Effects

Tibolone and Δ4-tibolone demonstrate clinically significant androgenic activity:

Receptor Characteristics:

• Tibolone parent compound: AR agonist
• Δ4-tibolone: AR agonist (moderate affinity)
• 3α-/3β-hydroxytibolone: AR antagonists (balancing effect)

Clinical Effects:

• Improved libido and sexual function
• Positive effects on mood and well-being
• Potential for androgenic side effects (acne, hirsutism - rare)

Glucocorticoid and Mineralocorticoid Activity

Antagonist Effects

Tibolone and its metabolites demonstrate receptor antagonism:

Glucocorticoid Receptor:

• Tibolone: Weak antagonist
• 3α-/3β-hydroxytibolone: Antagonists
• Clinical significance unclear

Mineralocorticoid Receptor:

• Tibolone: Weak antagonist
• 3α-/3β-hydroxytibolone: Antagonists
• May contribute to lack of fluid retention

Integrated Mechanism Summary

Net Tissue Effects

Bone:

• ↓ Bone resorption (estrogenic metabolites)
• ↑ Bone mineral density
• ↓ Fracture risk

Endometrium:

• Estrogenic stimulation attenuated
• Progestogenic opposition maintained
• Atrophic endometrium typically results

Breast:

• Sulfatase inhibition reduces local estrogen
• Progestogenic/androgenic activity
• Net antiproliferative (in women without breast cancer)
• Increased recurrence in women WITH breast cancer

Brain:

• ↓ Hot flashes (estrogenic/androgenic)
• Improved mood
• Improved sexual function (androgenic)

Vagina:

• Improved lubrication
• Improved epithelial maturation
• Reduced dyspareunia

3. FDA-Approved Indications

United States Regulatory Status

NOT FDA APPROVED

Tibolone is not approved by the FDA and is not legally available in the United States for any indication.

Regulatory History:

• 2005: Organon Pharmaceuticals submitted New Drug Application (NDA) for tibolone for treatment of vasomotor symptoms and prevention of osteoporosis
• June 2006: FDA issued "Not Approvable" letter citing:
  • Concerns about stroke risk (based on preliminary LIFT data)
  • Request for additional safety data
  • Benefit-risk balance concerns
• 2008: LIFT trial published confirming stroke risk (HR 2.30)
• Post-2008: No subsequent approval attempts

Why FDA Declined Approval

The FDA's decision was based on several factors:

1. Stroke Risk: Increased stroke risk observed in LIFT trial, particularly in older women
2. Unclear Benefit-Risk: Efficacy for vasomotor symptoms lower than combined HRT
3. Available Alternatives: Multiple FDA-approved options for same indications
4. Safety Signal Timing: Emerging data during review period raised concerns

International Approved Indications

European Medicines Agency (EMA) Approved Indications

1. Treatment of Menopausal Symptoms:

• Indicated for symptoms of estrogen deficiency in postmenopausal women
• Must be more than 12 months since last menstrual period
• Primary target: Vasomotor symptoms (hot flashes, night sweats)

2. Prevention of Osteoporosis:

• Prevention of bone loss in postmenopausal women at high risk of fractures
• For women intolerant of or contraindicated for other osteoporosis therapies
• Alternative when other preventive therapies not appropriate

Regional Approval Summary

Off-Label Considerations

Potential Off-Label Uses (Non-US)

In countries where tibolone is available, physicians may consider:

1. Sexual Dysfunction: Androgenic effects beneficial for libido
2. Mood Symptoms: Effects on well-being and mood
3. Vulvovaginal Atrophy: Improvement in vaginal symptoms

Access in the United States

• No legal avenue for prescription in US
• Personal importation is FDA regulated and generally not permitted
• Clinical trials may provide access (none currently active)

4. Dosing and Administration

Standard Dosing Regimens

Menopausal Symptoms (Livial)

Standard Dose:

• Dose: 2.5 mg once daily
• Administration: Oral, with or without food
• Timing: Take at the same time each day
• Duration: Continuous daily therapy, not cyclical

Initiation:

• Must be at least 12 months since last menstrual period
• Earlier use may cause irregular bleeding
• Switch from cyclic HRT: Start after completion of cycle
• Switch from continuous HRT: Can start immediately

Osteoporosis Prevention

Investigated Dose (LIFT Trial):

• Dose: 1.25 mg once daily
• Administration: Oral
• Note: This lower dose showed fracture efficacy but is not widely marketed

Standard Clinical Practice:

• 2.5 mg dose typically used
• 1.25 mg preparations not universally available

Administration Guidelines

Oral Administration

Instructions:

• Swallow tablet whole with water
• Can be taken with or without food
• Consistent daily timing recommended
• Do not crush or chew tablets

Missed Doses:

• If within 12 hours of usual time: Take as soon as remembered
• If more than 12 hours: Skip missed dose, take next at usual time
• Never take two tablets to make up for missed dose

Dose Adjustments

No Standard Adjustments Required

Standard Population:

• No dose adjustment for body weight
• No dose adjustment for mild-moderate renal impairment
• No dose adjustment for mild hepatic impairment

Special Situations

Hepatic Impairment:

Renal Impairment:

Available Formulations

Livial (Organon/Merck)

Tablet Formulation:

• Strength: 2.5 mg
• Appearance: White, round, flat tablet marked "Organon" and star logo
• Pack sizes: 28 tablets (1 month supply)

Other Brand Names (Select Markets)

Duration of Therapy

Menopausal Symptoms

Treatment Duration Principles:

• Use lowest effective dose for shortest duration
• Re-evaluate need periodically (at least annually)
• Gradual discontinuation may reduce symptom rebound
• Individual benefit-risk assessment

Osteoporosis Prevention

Duration Considerations:

• Continue while fracture risk remains elevated
• No established maximum duration
• Periodic reassessment recommended
• Consider transition to other therapies if stroke risk factors develop

Switching Protocols

From Combined HRT to Tibolone

• Complete current HRT cycle (if cyclical)
• Start tibolone the day after stopping HRT
• Withdrawal bleed may occur during transition

From Tibolone to Other Therapies

• Can switch directly to combined HRT
• No washout period required
• Consider reason for switch (efficacy, side effects)

5. Pharmacokinetics

Absorption

Oral Bioavailability

Tibolone demonstrates excellent oral absorption:

Absorption Characteristics:

• Mean oral bioavailability: ~92%
• Rapid and complete absorption from GI tract
• First-pass metabolism is significant but not limiting

Time to Peak Concentration:

• Tibolone parent: Not well characterized (rapid metabolism)
• 3α-hydroxytibolone: Tmax 1-2 hours
• 3β-hydroxytibolone: Tmax 1-2 hours
• Δ4-tibolone: Tmax 1-2 hours

Peak Concentrations (After 2.5 mg dose):

Food Effects

• No significant effect on extent of absorption
• Minor effect on rate of absorption
• Can be administered without regard to meals

Distribution

Volume of Distribution

• Large volume of distribution reflecting tissue uptake
• Distributes to target tissues including bone, breast, endometrium, brain

Protein Binding

• Plasma protein binding: 96.3%
• Primarily bound to albumin
• Binding is not saturated at therapeutic concentrations

Tissue Distribution

Active Metabolite Distribution:

• 3α-hydroxytibolone: Major circulating estrogenic metabolite
• 3β-hydroxytibolone: Lower circulating levels (~4-fold less than 3α)
• Δ4-tibolone: Lower circulating levels than hydroxy metabolites

Reservoir Formation:

• ~80% of total dose circulates as 3α-sulfated tibolone (inactive)
• This sulfated conjugate serves as reservoir
• Reconversion to active 3α-hydroxytibolone occurs in tissues

Metabolism

First-Pass Metabolism

Tibolone undergoes rapid and extensive hepatic metabolism:

Primary Metabolic Pathways:

1. 3α-Hydroxysteroid Dehydrogenase:

   • Converts tibolone → 3α-hydroxytibolone
   • Hepatic and intestinal enzyme
   • Major pathway

2. 3β-Hydroxysteroid Dehydrogenase:

   • Converts tibolone → 3β-hydroxytibolone
   • Hepatic and intestinal enzyme
   • Secondary pathway

3. Δ5-4-Isomerase:

   • Converts tibolone → Δ4-tibolone
   • Produces progestogenic/androgenic metabolite

Sulfation

Sulfotransferase Activity:

• 3α-hydroxytibolone undergoes sulfation
• 3α-sulfated tibolone is major circulating form
• Inactive reservoir that can be reconverted

Tissue-Specific Metabolism

Key Concept: Local metabolism determines tissue effects

In Breast Tissue:

• High sulfotransferase activity
• Metabolites rapidly inactivated
• Sulfatase is inhibited by 3α-hydroxytibolone
• Net effect: Reduced local estrogen exposure

In Bone/Brain/Vagina:

• Lower sulfotransferase activity
• Active estrogenic metabolites persist
• Net effect: Estrogenic stimulation

Elimination

Half-Life

Parent Compound and Metabolites:

Clinical Implications:

• Daily dosing appropriate despite long parent half-life
• Active metabolite half-lives support once-daily dosing
• Steady state achieved within 1-2 weeks

Excretion Routes

Primary Excretion:

• Feces: ~60%
• Urine: ~40%
• Primarily as sulfated and glucuronidated conjugates

Pharmacokinetic Considerations

Age Effects

• No significant effect of age on Cmax, Tmax, or t½
• Elderly women can use standard dosing
• LIFT trial included women aged 60-85

Accumulation

• Minimal accumulation with daily dosing
• Steady-state concentrations predictable
• No dose adjustment needed for long-term use

Pharmacokinetic Interactions

• CYP3A4 inhibitors/inducers may affect metabolism
• Clinical significance generally limited
• No major drug interaction contraindications

Comparative Pharmacokinetics

vs Conventional Estrogens

The superior bioavailability of tibolone compared to oral estradiol reflects its 19-nortestosterone structure, which is more resistant to first-pass conjugation.

6. Side Effects and Adverse Reactions

Common Side Effects (≥5% Incidence)

Vaginal Bleeding/Spotting

The most clinically relevant common side effect:

Incidence:

• 9.5% tibolone vs 2.5% placebo (clinical trials)
• Less frequent than combined continuous HRT (18-27% vs 47%)
• Usually occurs in first months of treatment

Characteristics:

• Typically light spotting
• Usually decreases over time
• Should be investigated if persistent or heavy

Management:

• Reassurance about expected decrease
• Ensure adequate time since menopause (≥12 months)
• Gynecological evaluation if persistent beyond 6 months
• Rule out endometrial pathology

Hot Flashes (Paradoxical)

Incidence:

• May initially worsen in some patients
• Generally improves with continued therapy
• Less effective than combined HRT for severe symptoms

Breast Pain/Tenderness

Incidence:

• Less common than with conventional HRT
• 2-4% of patients
• Usually mild and transient

Comparison:

• Lower incidence than estrogen + progestogen combinations
• May reflect androgenic counterbalancing

Weight Gain

Incidence:

• Variable reports in clinical trials
• May reflect androgenic activity
• Generally modest (<2 kg)

Abdominal Pain/Bloating

Incidence:

• 3-5% of patients
• Usually mild
• May improve with continued use

Serious Adverse Events

Stroke (CRITICAL SAFETY SIGNAL)

LIFT Trial Data:

Risk Characterization:

• Absolute risk increase: ~6 per 1,000 women per year
• Risk primarily in women aged 60-85 (LIFT population)
• Risk in younger women less well characterized
• Trial stopped early due to this finding

Risk Factors:

• Age ≥60 years (primary risk factor)
• Hypertension
• Diabetes
• Prior stroke/TIA
• Smoking
• Atrial fibrillation

Clinical Implications:

• Tibolone NOT recommended for women over age 60
• Carefully assess stroke risk factors before prescribing
• Consider alternatives in women with risk factors

Breast Cancer Recurrence (CRITICAL SAFETY SIGNAL)

LIBERATE Trial Data:

Subgroup Analysis:

Clinical Implication:

• CONTRAINDICATED in women with history of breast cancer
• Risk especially elevated in AI-treated patients
• ER-positive cancers at highest risk

Breast Cancer Incidence (New Cancers)

Contrasting Evidence:

Interpretation:

• LIFT: RCT in women without breast cancer - protective effect
• MWS: Observational study - possible selection bias
• LIBERATE: RCT in breast cancer survivors - HARMFUL
• Net effect: Protective in healthy women, harmful in survivors

Venous Thromboembolism (VTE)

Clinical Trial Data:

• Cochrane review: OR 0.44 (95% CI 0.09-2.14) vs placebo
• No statistically significant increase
• Lower risk than combined oral HRT

Comparison with Other HRT:

Endometrial Cancer

Evidence Summary:

Clinical Interpretation:

• Conflicting evidence
• RCT data does not show significant increase
• Observational studies suggest possible increase
• Monitor any abnormal bleeding

Cardiovascular Events

LIFT Trial - Coronary Events:

• No significant increase in myocardial infarction
• No significant increase in cardiovascular mortality
• Favorable lipid effects observed

Cochrane Review:

• OR 0.63 (95% CI 0.24-1.66) for cardiovascular events
• Not statistically significant

Laboratory Abnormalities

Lipid Changes

Generally Favorable:

• LDL cholesterol: Decreased 10-15%
• Total cholesterol: Decreased 5-10%
• Triglycerides: Variable (may increase)
• HDL cholesterol: May decrease slightly

Clinical Significance:

• Net cardiovascular effect unclear
• Lipid changes do not translate to CHD benefit in trials

Liver Function Tests

• Minimal effect on transaminases
• No routine monitoring required
• Contraindicated in severe hepatic impairment

Discontinuation Due to Adverse Events

Clinical Trial Data:

• Similar discontinuation rates to placebo
• Most common reasons:
  • Vaginal bleeding
  • Breast tenderness
  • Hot flash inadequacy

7. Drug Interactions

Cytochrome P450 Interactions

CYP3A4 Inducers

Tibolone metabolism may be affected by potent CYP3A4 inducers:

Strong CYP3A4 Inducers:

Clinical Impact:

• May reduce effectiveness for vasomotor symptoms
• May reduce bone protective effects
• Consider dose increase or alternative therapy

CYP3A4 Inhibitors

Strong CYP3A4 Inhibitors:

Clinical Impact:

• Potential for increased adverse effects
• Generally not clinically significant
• No specific dose adjustments established

Anticoagulant Interactions

Warfarin

Important Interaction:

• Tibolone may increase sensitivity to warfarin
• INR elevation possible
• Mechanism: Unknown; may affect vitamin K metabolism

Management:

• Baseline INR before tibolone initiation
• Frequent INR monitoring during first weeks
• Warfarin dose adjustment as needed

Direct Oral Anticoagulants (DOACs)

• Limited interaction data
• Monitor for signs of bleeding
• No specific contraindication

Hormone-Related Interactions

Other Estrogens

Concurrent Use Not Recommended:

• Duplication of hormonal effects
• No additive benefit expected
• Increased adverse effect risk

Antiestrogens (Tamoxifen, Raloxifene)

Pharmacologic Antagonism:

• Conflicting receptor effects
• Do not use concurrently
• LIBERATE trial showed increased recurrence risk with tibolone after tamoxifen

Aromatase Inhibitors

CRITICAL INTERACTION:

• LIBERATE showed highest recurrence risk in AI-treated women (HR 2.42)
• Tibolone may overcome AI-induced estrogen suppression
• CONTRAINDICATED in breast cancer patients

Antiepileptic Drug Interactions

Enzyme-Inducing AEDs

Non-Inducing AEDs

• Levetiracetam: No interaction expected
• Valproic acid: No significant interaction
• Lamotrigine: No significant interaction

Antiretroviral Interactions

Protease Inhibitors

• Ritonavir, lopinavir may increase tibolone exposure
• Clinical significance unclear
• Monitor for adverse effects

NNRTIs

• Efavirenz: May reduce tibolone levels (CYP3A4 induction)
• Nevirapine: May reduce tibolone levels
• Consider interaction potential

Other Interactions

Thyroid Hormones

• Estrogens can increase TBG levels
• May require thyroid dose adjustment
• Monitor thyroid function

Corticosteroids

• No pharmacokinetic interaction
• Both may affect bone metabolism
• Consider cumulative effects

Cholestyramine/Bile Acid Sequestrants

• May reduce tibolone absorption
• Separate administration by 4+ hours

8. Contraindications

Absolute Contraindications

Known or Suspected Breast Cancer

CRITICAL CONTRAINDICATION

Evidence:

• LIBERATE trial: 40% increased recurrence risk
• Applies to current or past breast cancer
• No safe interval after breast cancer treatment

Includes:

• Active breast cancer
• History of treated breast cancer
• DCIS (ductal carcinoma in situ)
• High genetic risk (BRCA1/2) - relative contraindication

Known or Suspected Estrogen-Dependent Malignancy

Applies to:

• Endometrial cancer (active or history)
• Other estrogen-responsive tumors
• Ovarian cancer (unclear evidence)

Undiagnosed Abnormal Vaginal Bleeding

Rationale:

• Must exclude malignancy before initiating
• Tibolone can mask or cause bleeding
• Complete evaluation required first

Active or History of Venous Thromboembolism

Includes:

• Deep vein thrombosis
• Pulmonary embolism
• Retinal vein thrombosis

Note: Evidence for tibolone VTE risk is less clear than for oral estrogens, but contraindication maintained as precaution

Active or Recent Arterial Thromboembolic Disease

Includes:

• Stroke (any type)
• Myocardial infarction
• Transient ischemic attack
• Active angina

Known Thrombophilic Disorders

Includes:

• Factor V Leiden mutation
• Protein C deficiency
• Protein S deficiency
• Antithrombin deficiency
• Antiphospholipid syndrome

Severe Hepatic Impairment

Rationale:

• Extensive hepatic metabolism required
• Accumulation and altered metabolism possible
• Unpredictable effects on coagulation

Porphyria

• May exacerbate porphyria
• All hormonal preparations contraindicated

Pregnancy

• Not applicable (postmenopausal indication)
• Theoretical risk if inadvertent exposure
• Pregnancy must be excluded before initiation

Breastfeeding

• Not applicable to target population
• Contraindicated if applicable

Known Hypersensitivity

• To tibolone or any excipients
• Cross-reactivity patterns unknown

Relative Contraindications/Precautions

Age Over 60 Years

CRITICAL PRECAUTION:

• LIFT trial showed increased stroke risk in ages 60-85
• Stroke HR 2.30 in this population
• Consider alternatives in older women

Stroke Risk Factors

Assess Before Prescribing:

• Hypertension (especially poorly controlled)
• Diabetes mellitus
• Smoking
• Obesity
• Atrial fibrillation
• Family history of stroke
• Prior TIA

Endometriosis

• May reactivate endometriotic implants
• Estrogenic activity may stimulate disease
• Use with caution if endometriosis history

Uterine Fibroids

• May increase fibroid size
• Monitor if history of fibroids
• Discontinue if significant growth

Migraine

• May exacerbate migraines in some women
• Particular concern with aura (stroke risk)
• Consider alternatives in severe migraine

Hypertriglyceridemia

• May increase triglycerides
• Caution if baseline >300 mg/dL
• Monitor lipids

Diabetes Mellitus

• Stroke risk factor
• May affect glucose metabolism
• Monitor glycemic control

Gallbladder Disease

• May increase gallbladder disease risk
• History of cholelithiasis requires caution

9. Special Populations

Geriatric Patients

Age Considerations

CRITICAL: Tibolone use should be approached with extreme caution in women over 60

LIFT Trial Population:

• Average age: 68 years (range 60-85)
• Stroke risk (HR 2.30) observed in this population
• Trial stopped early due to safety signal

Current Recommendations:

• NOT recommended for women over 60
• If used, strict risk-benefit assessment required
• Consider alternatives (e.g., transdermal estrogen, bisphosphonates)

Efficacy in Elderly

Despite safety concerns, LIFT demonstrated efficacy:

• Vertebral fracture reduction: 50%
• Nonvertebral fracture reduction: 26%
• Breast cancer incidence reduction: 68%

However: Stroke risk outweighs benefits in most elderly women

Perimenopausal Women

Timing of Initiation

NOT appropriate for perimenopause:

• Must be at least 12 months since last menstrual period
• Earlier use associated with irregular bleeding
• Not approved for perimenopausal symptoms

Transition from Perimenopause

• Wait until clearly postmenopausal
• Consider HRT during perimenopause if needed
• Switch to tibolone after establishing menopause

Hepatic Impairment

Pharmacokinetic Considerations

• Extensive hepatic metabolism
• Clearance reduced in hepatic impairment
• Metabolite ratios may be altered

Dosing Recommendations

Renal Impairment

Pharmacokinetic Considerations

• Dual elimination (40% renal, 60% fecal)
• Moderate renal impairment: No major changes expected
• Severe impairment: Limited data

Dosing Recommendations

Patients with Cardiovascular Risk Factors

Risk Assessment Required

Before initiating tibolone, assess:

• Blood pressure control
• Lipid profile
• Diabetes status
• Smoking status
• BMI
• Family history

High-Risk Patients

Consider alternatives for patients with:

• Multiple cardiovascular risk factors
• Prior cardiovascular events
• Poorly controlled hypertension
• Diabetes with complications

Patients with Osteoporosis

Appropriate Use

Tibolone may be considered when:

• Vasomotor symptoms present
• Osteoporosis prevention needed
• Patient under age 60
• No contraindications present

Efficacy Data (LIFT Trial)

• BMD increase: 3.2% spine, 2.9% hip
• Vertebral fracture: 50% reduction
• Nonvertebral fracture: 26% reduction

Sexual Dysfunction

Potential Benefits

Tibolone's androgenic activity provides:

• Improved libido
• Improved sexual arousal
• Improved satisfaction

Patient Selection

May be appropriate for women with:

• Hypoactive sexual desire disorder
• Concurrent menopausal symptoms
• No contraindications

Surgical Patients

Perioperative Management

Recommendations:

• Discontinue 4-6 weeks before major surgery
• Resume after full mobilization
• Consider VTE prophylaxis if surgery needed urgently

10. Monitoring Parameters

Pre-Treatment Evaluation

Required Assessments

Medical History:

• Complete menstrual history
• Confirm menopausal status (≥12 months amenorrhea)
• Breast cancer history (CONTRAINDICATION)
• Cardiovascular/stroke history
• VTE history
• Hepatic disease history

Physical Examination:

• Blood pressure measurement
• Breast examination
• Pelvic examination
• BMI/weight

Laboratory Testing:

• Lipid panel (baseline)
• Liver function tests (baseline)
• Mammography (within past year)
• Pap smear (per guidelines)

Risk Assessment:

• Stroke risk assessment (CRITICAL)
• VTE risk assessment
• Breast cancer risk assessment
• Cardiovascular risk assessment

Ongoing Monitoring

Visit Schedule

Clinical Monitoring

At Each Visit:

• Blood pressure
• Weight
• Symptom assessment (hot flashes, vaginal symptoms)
• Adverse event query
• Bleeding pattern assessment
• Breast examination (annually)

Symptom Documentation:

• Vasomotor symptom frequency/severity
• Vaginal symptom improvement
• Mood and well-being
• Sexual function (if relevant)

Laboratory Monitoring

Routine Monitoring

Special Circumstances

• Thyroid function: If on thyroid replacement
• Coagulation studies: If on anticoagulants
• Endometrial assessment: If abnormal bleeding

Specific Safety Monitoring

Abnormal Vaginal Bleeding

Evaluation Required:

• Any bleeding after first 6 months
• Heavy or prolonged bleeding
• Bleeding with other symptoms

Investigations:

• Transvaginal ultrasound
• Endometrial biopsy if indicated
• Consider hysteroscopy

Stroke Warning Signs (Patient Education)

FAST Signs:

• Face drooping
• Arm weakness
• Speech difficulty
• Time to call emergency services

Additional Symptoms:

• Sudden severe headache
• Vision changes
• Confusion
• Dizziness/loss of balance

Breast Monitoring

Recommendations:

• Monthly breast self-examination
• Annual clinical breast examination
• Mammography per screening guidelines
• Report any changes immediately

Reassessment of Need

Duration of Therapy Review

At Each Annual Visit:

• Reassess ongoing need for treatment
• Evaluate continued benefit-risk
• Consider trial discontinuation
• Discuss alternatives

Indications to Discontinue

• Development of contraindication
• New stroke risk factors
• Age-related risk increase (approaching/passing 60)
• Inadequate symptom control
• Patient preference
• Completion of treatment goal

11. Cost and Availability

Global Availability

United States

NOT AVAILABLE

• FDA did not approve (2006 "Not Approvable" letter)
• No legal commercial source
• No generic available
• Clinical trials: None currently active

Europe

WIDELY AVAILABLE

• Brand name: Livial (Organon/Merck)
• Available in most EU countries
• Prescription required
• Multiple generic versions available in some markets

Other Regions

Pricing Information

European Pricing (Approximate)

Livial 2.5 mg (28 tablets):

Note: Pricing varies significantly by country and insurance coverage

Generic Availability (Non-US)

• Generic tibolone available in some European markets
• Lower cost than branded Livial
• Quality and bioequivalence regulations apply

Insurance and Reimbursement

Europe

• Generally covered by national health systems
• UK: Available on NHS prescription
• Germany: Covered by statutory health insurance
• Private insurance: Usually covered

Australia

• Listed on Pharmaceutical Benefits Scheme (PBS)
• Subsidized cost to patients

Access Alternatives

For US Patients

No legal pathway exists for routine use:

1. No FDA-approved product
2. Personal importation generally not permitted
3. Compounding pharmacies cannot legally prepare
4. Online international pharmacies: Legal/safety concerns

Alternative Options:

• FDA-approved HRT options (numerous choices)
• Ospemifene for vulvovaginal symptoms
• Non-hormonal options for vasomotor symptoms

Comparative Costs

vs Other Menopausal Therapies (Approximate Monthly Cost)

12. Clinical Evidence Summary

Pivotal Clinical Trials

LIFT Trial (Long-Term Intervention on Fractures with Tibolone)

Study Design:

• Phase 3, randomized, double-blind, placebo-controlled
• 4,538 postmenopausal women aged 60-85
• T-score ≤-2.5 or ≤-2.0 with prevalent fracture
• Tibolone 1.25 mg vs placebo
• Primary endpoint: Vertebral fracture incidence

Efficacy Results:

Safety Results:

Trial Outcome:

• Stopped early (Feb 2006) due to stroke safety signal
• Despite proven fracture efficacy, stroke risk deemed unacceptable
• Led to FDA non-approval

LIBERATE Trial (Livial Intervention Following Breast Cancer)

Study Design:

• Randomized, double-blind, placebo-controlled
• 3,148 breast cancer survivors with vasomotor symptoms
• Tibolone 2.5 mg vs placebo
• Primary endpoint: Breast cancer recurrence

Key Results:

Efficacy for Symptoms:

• Significant reduction in hot flash frequency
• Improved quality of life measures
• Improved vaginal symptoms

Safety (Primary Endpoint):

Subgroup Findings:

• Highest risk: Aromatase inhibitor users (HR 2.42)
• ER-positive tumors: HR 1.56
• ER-negative tumors: HR 1.15 (NS)

Trial Outcome:

• Stopped early (July 2007)
• Contraindication established for breast cancer survivors

Cochrane Systematic Review (2016)

Analysis Scope:

• 46 RCTs included
• Various comparisons: tibolone vs placebo, HRT, other therapies

Key Findings:

vs Placebo:

• Vasomotor symptoms: Significantly reduced
• Unscheduled bleeding: Increased (OR 2.79)
• VTE: No significant difference (OR 0.44)

vs Combined HRT:

• Vasomotor symptoms: Less effective than HRT
• Unscheduled bleeding: Less than HRT (OR 0.32)
• Breast symptoms: Less with tibolone

Endometrial Safety:

• No significant increase in endometrial cancer in RCTs
• OR 1.47 (95% CI 0.23-9.33)

Bone Density Studies

Meta-Analysis of BMD Effects

Findings:

• Spine BMD: +3.2% vs placebo (p<0.001)
• Hip BMD: +2.9% vs placebo (p<0.001)
• Comparable to conventional HRT
• Maintained with long-term use

Sexual Function Studies

Multiple RCTs

Consistent Findings:

• Improved libido (androgenic effect)
• Improved arousal
• Improved overall sexual satisfaction
• Superior to estrogen-only therapy for sexual function

Cardiovascular Studies

Lipid Effects

Consistent Pattern:

• LDL cholesterol: Decreased 10-15%
• Total cholesterol: Decreased 5-10%
• HDL cholesterol: May decrease slightly
• Triglycerides: Variable

Clinical Significance:

• Favorable lipid changes do not translate to CHD benefit
• Stroke risk increase concerning

Observational Studies

Million Women Study

Key Finding:

• Tibolone users: RR 1.45 for breast cancer vs never-users
• Contrasts with LIFT trial finding of protection
• Possible explanations: Selection bias, different populations

Interpretation:

• Observational vs RCT data conflict
• RCT (LIFT) more reliable for causation
• LIBERATE confirms harm in breast cancer SURVIVORS

13. Comparison with Alternatives

Comparison with Combined HRT

Tibolone vs Estrogen + Progestogen

When to Prefer Tibolone:

• Libido is a primary concern
• Breast tenderness with HRT
• Bleeding problems with HRT
• Desire for simple regimen

When to Prefer Combined HRT:

• Severe vasomotor symptoms
• Need maximum symptom control
• Younger women (<60)

Comparison with Estrogen Alone

Tibolone vs Unopposed Estrogen (Hysterectomized Women)

Comparison with SERMs

Tibolone vs Raloxifene

When to Prefer Tibolone:

• Menopausal symptoms present
• Libido improvement desired
• VTE concern

When to Prefer Raloxifene:

• Breast cancer prevention priority
• No menopausal symptoms
• US patients (availability)

Comparison with Non-Hormonal Options

For Vasomotor Symptoms

Comparison with Ospemifene

For Vulvovaginal Symptoms

Unique Positioning Summary

Tibolone Advantages:

1. Single-compound therapy
2. Androgenic benefits for libido
3. Less breast tenderness than HRT
4. Lower VTE risk than oral HRT
5. Lower bleeding than combined HRT

Tibolone Disadvantages:

1. Not available in US
2. Stroke risk in elderly (>60)
3. Contraindicated after breast cancer
4. Less effective for severe hot flashes than HRT

14. Goal Archetype Integration

Tissue-Selective Steroid Classification

STEAR Mechanism Overview

Tibolone represents a unique archetype within hormone therapy: the Selective Tissue Estrogenic Activity Regulator (STEAR). Unlike SERMs that achieve tissue selectivity through receptor binding characteristics, tibolone achieves selectivity through differential local metabolism.

Archetype Positioning:

• Category: Synthetic tissue-selective steroid
• Primary Role: Menopause symptom management with multi-system benefits
• Distinguishing Feature: Single compound providing estrogenic, progestogenic, AND androgenic activity

Goal Alignment Matrix

Menopause-Specific Considerations

Optimal Patient Profile

Tibolone is ideally suited for:

Preferred Candidates:

• Postmenopausal women aged 45-59
• Multiple menopausal symptoms (vasomotor + sexual + vaginal)
• Low libido as significant concern
• Intolerance to combined HRT (breast tenderness, bleeding)
• Desire for simplified single-agent therapy

Less Ideal Candidates:

• Women over age 60 (stroke risk)
• Severe vasomotor symptoms requiring maximum efficacy
• History of breast cancer (CONTRAINDICATED)
• Significant stroke risk factors

Symptom Response Expectations

15. Age-Stratified Dosing

Age-Based Risk-Benefit Analysis

Ages 45-54: Early Postmenopause

Risk Profile:

• Lowest cardiovascular risk
• Peak menopausal symptom burden
• Maximum benefit-to-risk ratio

Dosing Recommendation:

• Standard dose: 2.5 mg once daily
• No dose adjustment required
• Duration: As needed for symptom control

Monitoring Focus:

• Symptom response
• Bleeding patterns (first 6 months)
• Breast examination

Ages 55-59: Mid-Postmenopause

Risk Profile:

• Moderate cardiovascular risk
• Symptoms may persist or re-emerge
• Benefit-to-risk ratio remains favorable

Dosing Recommendation:

• Standard dose: 2.5 mg once daily
• Consider cardiovascular risk assessment
• Duration: Re-evaluate annually

Monitoring Focus:

• Cardiovascular risk factors
• Blood pressure
• Lipid profile
• Symptom necessity

Ages 60-64: Late Postmenopause

Risk Profile:

• ELEVATED STROKE RISK (LIFT trial population)
• Benefit-to-risk ratio shifts unfavorably
• Alternative therapies often preferred

Dosing Recommendation:

• Generally NOT RECOMMENDED
• If used: 2.5 mg with comprehensive risk assessment
• Consider alternative therapies first:
  • Transdermal estradiol (lower VTE/stroke risk)
  • Non-hormonal options (fezolinetant, SSRIs)
  • Vaginal estrogen only (if GSM is primary concern)

Monitoring Focus:

• Frequent cardiovascular assessment
• Stroke warning sign education
• Blood pressure control
• Consider discontinuation pathway

Ages 65+: Advanced Postmenopause

Risk Profile:

• HIGHEST STROKE RISK
• LIFT trial stopped early due to stroke signal in 60-85 age group
• Benefit-to-risk ratio generally unfavorable

Dosing Recommendation:

• NOT RECOMMENDED for initiation
• If continuing from earlier use: Evaluate discontinuation
• Alternatives strongly preferred

If Continuation Necessary:

• Comprehensive informed consent
• Quarterly monitoring
• Document rationale
• Clear discontinuation criteria

Age-Specific Dosing Summary Table

Duration Guidelines by Age

16. Drug Interactions (Expanded Clinical Guidance)

Critical Interactions Requiring Action

Breast Cancer Therapies

Aromatase Inhibitors (Anastrozole, Letrozole, Exemestane):

• Interaction Severity: CONTRAINDICATED
• Mechanism: Tibolone bypasses AI-induced estrogen suppression
• Clinical Evidence: LIBERATE trial HR 2.42 for recurrence in AI users
• Action: Never combine; contraindicated in breast cancer survivors

Tamoxifen:

• Interaction Severity: CONTRAINDICATED
• Mechanism: Pharmacologic antagonism + tibolone estrogenic effects
• Clinical Evidence: LIBERATE trial HR 1.25 for recurrence
• Action: Do not use in breast cancer patients regardless of tamoxifen status

Anticoagulants

Warfarin:

• Interaction Severity: Significant
• Effect: Increased anticoagulant sensitivity
• Mechanism: Unknown; possibly vitamin K metabolism
• Management:
  • Baseline INR before tibolone initiation
  • Check INR at days 7, 14, 28 after starting
  • Anticipate 10-20% warfarin dose reduction
  • Maintain frequent monitoring until stable

DOACs (Apixaban, Rivaroxaban, Edoxaban):

• Interaction Severity: Unknown/Low
• Data: Limited interaction studies
• Management: Standard DOAC monitoring; watch for bleeding signs

Moderate Interactions Requiring Monitoring

CYP3A4 Modulators

Strong Inducers (Reduce Tibolone Efficacy):

Strong Inhibitors (May Increase Tibolone Exposure):

Thyroid Medications

Levothyroxine:

• Interaction: Estrogens increase thyroxine-binding globulin (TBG)
• Effect: May reduce free T4, increase TSH
• Management:
  • Baseline TSH before tibolone
  • Recheck TSH at 6-12 weeks
  • Adjust levothyroxine dose (typically 10-20% increase needed)
  • Continue monitoring until stable

Low-Risk Interactions

Commonly Co-Administered Medications

Interaction Management Quick Reference

17. Bloodwork Impact

Hormone Panel Effects

Standard Female Hormone Panel

Interpretation Note: Standard E2 assays will NOT detect tibolone metabolites. Symptom response, not E2 levels, guides dosing.

Progesterone and Related Markers

Lipid Panel Effects

Expected Changes at 2.5 mg Daily

Clinical Interpretation:

• Net cardiovascular effect unclear despite favorable LDL changes
• HDL decrease partially offsets LDL benefit
• Triglyceride increase concerning in hypertriglyceridemia
• Do not rely on lipid improvements for CV risk reduction

Liver Function Tests

Coagulation Markers

Key Point: Tibolone has more favorable coagulation profile than oral estrogens, explaining lower VTE risk.

Glucose and Metabolic Markers

Bone Markers

Interpretation: Resorption markers decrease more than formation markers, indicating net bone-preserving effect.

Recommended Monitoring Schedule

18. Protocol Integration

Unique Mechanism: Tibolone vs Standard HRT (E2 + P4)

Fundamental Differences

Standard HRT (Estradiol + Progesterone):

• Two separate hormones with distinct receptors
• Systemic estrogen exposure uniform across tissues
• Progesterone added for endometrial protection
• Does not address androgen deficiency
• Requires coordination of cycling or continuous regimens

Tibolone:

• Single prodrug generating three active metabolites
• Tissue-selective through LOCAL METABOLISM
• Progestogenic and androgenic activity built-in
• Addresses androgen deficiency inherently
• Simplified once-daily dosing

Metabolic Selectivity Comparison

When to Choose Tibolone Over E2 + P4

Clear Tibolone Preference

1. Sexual dysfunction/low libido as primary concern

   • Androgenic metabolite provides direct benefit
   • E2 + P4 does not address androgen deficiency
   • No need to add testosterone separately

2. Breast tenderness with E2 + P4

   • Tibolone causes less breast stimulation
   • Sulfatase inhibition reduces local estrogen

3. Breakthrough bleeding on combined HRT

   • Tibolone causes less unscheduled bleeding
   • Atrophic endometrium typically results

4. Desire for simplified regimen

   • Single daily tablet vs multiple hormones
   • No cycling decisions required
   • Better adherence potential

5. VTE concern but need systemic therapy

   • Tibolone has lower VTE risk than oral E2
   • Alternative: Transdermal E2 (also low VTE)

Clear E2 + P4 Preference

1. Severe vasomotor symptoms

   • Combined HRT more effective for severe hot flashes
   • Tibolone moderate efficacy

2. Women over age 60

   • Tibolone contraindicated/cautioned due to stroke risk
   • Transdermal E2 + micronized P4 preferred

3. US patients (availability)

   • Tibolone not available in US
   • No legal access pathway

4. Preference for bioidentical hormones

   • Tibolone is synthetic 19-nortestosterone derivative
   • E2 + P4 can be bioidentical

5. Need for dose titration flexibility

   • E2 + P4 allows independent adjustment
   • Tibolone fixed 2.5 mg dose only

Protocol Switching Scenarios

Switching FROM E2 + P4 TO Tibolone

Indications for Switch:

• Breast tenderness despite dose adjustment
• Persistent breakthrough bleeding
• Sexual dysfunction not responding to E2 + P4
• Desire for simplified regimen

Switching Protocol:

1. Complete current HRT cycle if using cyclical regimen
2. Start tibolone 2.5 mg the day after stopping HRT
3. Expect potential withdrawal symptoms for 1-2 weeks
4. Reassess symptom control at 4-6 weeks
5. Document response to guide future decisions

Switching FROM Tibolone TO E2 + P4

Indications for Switch:

• Inadequate vasomotor symptom control
• Age approaching 60 (stroke risk)
• Development of stroke risk factors
• Patient preference for bioidentical therapy

Switching Protocol:

1. Stop tibolone
2. Start E2 + P4 the following day
3. No washout period required
4. Monitor for symptom changes during transition
5. Adjust E2 dose based on symptom response

Combination Considerations

What NOT to Combine with Tibolone

Acceptable Combinations with Tibolone

Protocol Decision Tree

MENOPAUSAL SYMPTOMS PRESENT
          |
          v
    Age < 60? ──────────────> NO ──> Avoid tibolone; consider
          |                          transdermal E2 + P4 or
          |                          non-hormonal options
          v
         YES
          |
          v
    Breast cancer history? ──> YES ──> TIBOLONE CONTRAINDICATED
          |                            Use non-hormonal options
          v
          NO
          |
          v
    Primary concern is
    sexual function/libido? ──> YES ──> Tibolone preferred
          |
          v
          NO
          |
          v
    Severe hot flashes
    requiring maximum
    efficacy? ─────────────> YES ──> E2 + P4 preferred
          |
          v
          NO
          |
          v
    Breast tenderness or
    bleeding issues on
    prior HRT? ────────────> YES ──> Tibolone preferred
          |
          v
          NO
          |
          v
    Patient in US? ─────────> YES ──> Tibolone not available;
          |                           use E2 + P4
          v
          NO
          |
          v
    Either tibolone OR E2 + P4 appropriate
    Individualize based on patient preference,
    access, and provider experience

Integration with Broader HRT Strategy

Position in Treatment Algorithm

First-Line Options (ages 45-59):

1. Transdermal estradiol + micronized progesterone (gold standard)
2. Tibolone (if libido concern, bleeding issues, or preference)
3. Oral combined HRT (if transdermal not tolerated)

Second-Line/Alternative:

• Switch between first-line options based on response
• Consider combination approaches if partial response

Special Populations:

• Hysterectomized: E2-only OR tibolone (both valid)
• Libido focus: Tibolone OR E2 + testosterone
• US patients: E2 + P4 (tibolone unavailable)
• Age 60+: Avoid tibolone; transdermal E2 preferred

19. Storage and Handling

Storage Requirements

Temperature

Recommended Storage:

• Store below 25°C (77°F)
• Protect from heat
• Room temperature storage acceptable

Light Protection

• Store in original blister pack
• Protect from excessive light
• Keep carton closed when not in use

Humidity

• Protect from moisture
• Do not store in bathroom
• Keep in dry environment

Handling Precautions

Healthcare Worker Safety

Standard Precautions:

• No special handling required
• Not cytotoxic
• Standard universal precautions apply
• Classified as anabolic steroid (Canada) - regulatory implications

Patient Handling

Instructions:

• Handle tablets with dry hands
• Take directly from blister pack
• Do not remove until ready to take
• Keep out of reach of children

Stability Information

Intact Packaging

• Shelf life: Typically 3 years from manufacture
• Check expiration date on carton
• Do not use after expiration

After Opening

• Use remaining tablets before expiration
• Keep in original packaging
• No special storage required

Disposal

Proper Disposal Methods

Recommended:

• Return to pharmacy for disposal
• Drug take-back programs
• Do not flush or pour down drain

Environmental Considerations

• Steroid hormone may affect aquatic organisms
• Proper disposal protects environment
• Follow local regulations

Transportation

Patient Transportation

• No special requirements
• Protect from extreme heat
• Keep in original packaging

Pharmaceutical Distribution

• Temperature-controlled shipping recommended
• Standard pharmaceutical handling
• Verify packaging integrity

15. References

Primary Literature

Pivotal Clinical Trials

1. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359(7):697-708.

2. Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial (LIBERATE). Lancet Oncol. 2009;10(2):135-146.

3. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 2002;87(1):16-23.

4. Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016;10(10):CD008536.

Pharmacology Studies

5. Kloosterboer HJ. Tissue-selectivity: the mechanism of action of tibolone. Maturitas. 2004;48 Suppl 1:S30-40.

6. Timmer CJ, Verheul HA, Doorstam DP. Pharmacokinetics of tibolone in early and late postmenopausal women. Br J Clin Pharmacol. 2002;54(2):101-106.

7. Verheul HA, Blok LJ, Burger CW, Hanifi-Moghaddam P, Kloosterboer HJ. Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestogen acetate. Reprod Sci. 2007;14(2):160-168.

Safety Studies

8. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-427.

9. Bundred NJ, Kenemans P, Yip CH, et al. Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Res. 2012;14(1):R13.

10. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007;92(3):911-918.

Cardiovascular/Stroke Studies

11. Ossewaarde ME, Bots ML, Verbeek AL, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology. 2005;16(4):556-562.

12. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005;12(6):716-727.

Clinical Guidelines

13. North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.

14. Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150.

15. National Institute for Health and Care Excellence (NICE). Menopause: diagnosis and management. NICE guideline [NG23]. 2015, updated 2019.

Review Articles

16. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001;76(1-5):231-238.

17. Palacios S, Mejía A. Progestogen safety and tolerance in hormonal replacement therapy. Expert Opin Drug Saf. 2016;15(11):1515-1525.

18. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas. 2005;51(1):21-28.

Regulatory Documents

19. European Medicines Agency. Livial Summary of Product Characteristics. Current version.

20. Food and Drug Administration. Complete Response Letter for Tibolone NDA. June 2006.

21. Therapeutic Goods Administration (Australia). Product Information: Livial. Current version.

Online Resources

22. DrugBank: Tibolone - https://go.drugbank.com/drugs/DB09070

23. PubChem: Tibolone - https://pubchem.ncbi.nlm.nih.gov/compound/444008

24. Australasian Menopause Society: Tibolone Information Sheet - https://www.menopause.org.au

Document History

Document Completion: 2025-12-26 Status: PAPER 46 OF 76 COMPLETE Next Paper: #47 - Armour Thyroid (NDT)